CJC-1295 (with DAC) vs Ipamorelin
Both have human endocrine pharmacology, but neither has established lifestyle efficacy and their mechanisms/duration differ.
| Attribute | CJC-1295 (with DAC) | Ipamorelin |
|---|---|---|
| Human evidence | Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy. | Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo. |
| Research focus | Growth-hormone axis research | GH-axis physiology and motility research |
| Regulatory status | Not FDA-approved; FDA lists CJC-1295 among substances with significant safety concerns in compounding. | Not FDA-approved; FDA lists safety concerns for compounded ipamorelin. |
| Route / formulation | CJC-1295 with DAC is not interchangeable with informal 'CJC without DAC' products. | The Phase II evidence was intravenous in postoperative patients and cannot be transferred to subcutaneous wellness/bodybuilding use. |
Why these are compared
These compounds appear in the gh-axis / body-composition interest evidence landscape, but they are not interchangeable. CJC-1295 (with DAC) is long-acting ghrh analogue peptide studied in growth-hormone axis research; Ipamorelin is ghrelin-receptor/gh secretagogue peptide studied in gh-axis physiology and motility research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
CJC-1295 (with DAC): Early human pharmacology with regulator safety concerns; unapproved.
Ipamorelin: Human Phase I/II exposure; tested Phase II indication was negative; no lifestyle efficacy established.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No head-to-head outcome trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.